Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Globe Newswire•09/11/2026•16:05 ET
0
Key Highlights
- ➤HORIZON enrollment exceeded target, with more than 50 AMKD patients across three cohorts
- ➤Final HORIZON data expected in early 2027; pivotal trial planned for first-half 2027
- ➤CIPheR enrollment ongoing; topline MZE782 PKU data expected in 2027
- ➤Cash, equivalents and marketable securities reached $477.0 million, funding operations into 2029
- ➤Q3 net loss widened to $48.0 million, or $0.79 per share, from $30.1 million
Expert Statements
Jason Coloma, Chief executive officer of Maze Therapeutics
“Completing enrollment in HORIZON with more than 50 patients across three cohorts marks an important milestone for MZE829 and exceeded our target enrollment of 10-15 patients per cohort.”
Jason Coloma, Chief executive officer of Maze Therapeutics
“HORIZON gives us the opportunity to generate a robust dataset across three distinct AMKD patient populations, including patients with and without diabetes and those with FSGS, and provide a comprehensive view of MZE829’s potential as a best-in-class therapy for a broad AMKD population, supported by its differentiated dual mechanism of action.”
Jason Coloma, Chief executive officer of Maze Therapeutics
“We are encouraged by the previously reported clinically meaningful uACR reductions demonstrated among 12 efficacy-evaluable patients in an interim data cut from HORIZON, look forward to reporting the complete HORIZON dataset in early 2027, and plan to use these results to inform our pivotal program.”
Jason Coloma, Chief executive officer of Maze Therapeutics
“We are also making strong progress with MZE782 with respect to both continued enrollment in the Phase 2 CIPheR trial in PKU and advancement of our plans to initiate a Phase 2 CKD trial in the first half of 2027.”
Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027
Enrollment ongoing in Phase 2 CIPheR trial of MZE782 in PKU; topline data expected in 2027
Get started
Create a free account to read the full story.